We Have a Proven Track Record of
Successful Alliances

In Wyeth you will find a partner who recognizes, and is committed to, the critical importance of partnering and who also possesses the capabilities to turn innovation into commercial success stories.

In fact, many of our partnerships have resulted in products that were first in class and created new markets by providing superior treatment options. Many of our partnered products are top performers in their categories, and Prevnar^®, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM₁₉₇ Protein), Enbrel^® (etanercept), and Zosyn^® (piperacillin/tazobactam) are among the top-selling Wyeth brands today.

Case Studies

Trubion Alliance	Methylnaltrexone
PROTONIX	INFUSE/InductOs (rhBMP-2, dibotermin alfa)

Selection of Successful Partnered Products

ENBREL
2007 Net Sales: $5.3 billion (including sales booked by our partner Amgen)*

PREVNAR
2007 Net Sales: $2.4 billion*

PROTONIX — Case Study
2007 Net Sales: $1.9 billion*

ZOSYN
2007 Net Sales: $1.1 billion*

Advil
2007 Net Sales: $684 million*

*Source: 2007 Annual Reports

218919-01